Background: Ceftobiprole is a cephalosporin that may be effective for treating complicated bacteremia, including methicillin-resistant .
Methods: In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated bacteremia were randomly assigned in a 1:1 ratio to receive ceftobiprole at a dose of 500 mg intravenously every 6 hours for 8 days and every 8 hours thereafter, or daptomycin at a dose of 6 to 10 mg per kilogram of body weight intravenously every 24 hours plus optional aztreonam (at the discretion of the trial-site investigators). The primary outcome, overall treatment success 70 days after randomization (defined as survival, bacteremia clearance, symptom improvement, no new bacteremia-related complications, and no receipt of other potentially effective antibiotics), with a noninferiority margin of 15%, was adjudicated by a data review committee whose members were unaware of the trial-group assignments.
The rapid evolution of wireless communication technologies (such as fifth-generation (5G) cellular networks) in the last years has allowed connecting different objects (from wearable electronics to vehicles) and people through communication networks, and at the same time, has led to widespread deployment of base stations. Along with this growth, questions about the potential adverse effects on human health due to electromagnetic fields (EMFs) from base station antennas have also been raised. In this paper, we focus on the assessment of EMFs in automobiles during short (between cities) and long (between countries) trips on several European roads.
View Article and Find Full Text PDFSARS-CoV-2 infects cells by attachment to its receptor-the angiotensin converting enzyme 2 (ACE2). Regardless of the wealth of structural data, little is known about the physicochemical mechanism of interactions of the viral spike (S) protein with ACE2 and how this mechanism has evolved during the pandemic. Here, we applied experimental and computational approaches to characterize the molecular interaction of S proteins from SARS-CoV-2 variants of concern (VOC).
View Article and Find Full Text PDF